| HOME >> BIOLOGY >> TECHNOLOGY |
common share for the nine months ended September 30, 2007 and 2006,
respectively. Research and development expense and general and
administrative expense includes $2,188 and $1,314 of non-cash
operating expenses determined in accordance with SFAS No. 123(R) for
the nine months ended September 30, 2007.
Anadys Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
September 30, December 31,
2007 2006
(Unaudited) (Audited)
Assets
Cash, cash equivalents and securities
available-for-sale $61,747 $82,149
Other current assets 1,316 2,116
Noncurrent assets 4,407 5,136
Total assets $67,470 $89,401
Liabilities and Stockholders' Equity
Current liabilities $4,209 $9,211
Other long-term liabilities 517 19,865
Stockholders' equity 62,744 60,325
Total liabilities and stockholders' equity $67,470 $89,401
| SOURCE Anadys Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |